Actively Recruiting
Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
Led by University Hospital, Angers · Updated on 2026-03-06
120
Participants Needed
1
Research Sites
83 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chemotherapy-induced cognitive disorders, such as memory problems, slowness of execution, inability to concentrate, and language difficulties, are sequelae that occur in patients undergoing chemotherapy or who have received chemotherapy. These symptoms lead to a degradation of the patients' quality of life and can have a significant social and familial impact. They are most commonly described in solid oncology, particularly in patients with breast cancer. Data about patients with hematological malignancies are scarce, but they seem to show the same phenomenon as in solid oncology. Indeed, many chemotherapies are used both in hematology and solid oncology and may therefore cause similar effects on cognition. Additionally, due to their mechanism of action, some chemotherapies specifically used in hematology could induce cognitive disorders. Hematology-treated patients are probably also affected by these disorders and may consequently experience a reduced quality of life. The objective of this study is to assess the changes in cognitive functions in patients receiving chemotherapy for the treatment of hematological malignancies, using neuropsychological tests and a self-administered questionnaire, compared to a control group, as well as their potential impact on quality of life, fatigue, anxiety, and depression.
CONDITIONS
Official Title
Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma
- Patient receiving a fixed-duration first-line chemotherapy
- Patient affiliated or beneficiary of a social security scheme
- Signed informed consent form
- Adult control group member who is a relative of the patient (spouse, sibling, friend, etc.)
- Control group member within 5 years age difference of the patient
- Control group member with the same educational level as the patient
- Control group member affiliated or beneficiary of a social security scheme
- Control group member signed informed consent form
You will not qualify if you...
- No patient's relative available for the control group
- Known or suspected cognitive disorders before chemotherapy
- History of severe neurological or psychiatric disorders (e.g., severe depression)
- Previous chemotherapy treatment
- Previous brain radiotherapy
- Ongoing treatments affecting cognition
- Patient unable to read
- Patient not speaking French
- Person deprived of liberty by judicial or administrative decision
- Person under forced psychiatric care
- Person under legal protection measures
- Person unable to express consent
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital of Angers
Angers, Maine et Loire, France, 49933
Actively Recruiting
Research Team
S
SCHMIDT ALINE, MD, PhD
CONTACT
D
Darras Elise, PharmD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here